PMID: 8451774Feb 1, 1993Paper

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

Therapeutic Drug Monitoring
S H SindrupL F Gram

Abstract

The relationship between the metabolism of the selective serotonin reuptake inhibitor citalopram and the sparteine and mephenytoin oxidation polymorphisms was studied in 24 healthy male volunteers, constituting panels of extensive metabolizers of sparteine and mephenytoin (n = 10), poor metabolizers of sparteine (n = 8), and poor metabolizers of mephenytoin (n = 6). Each subject was given 40 mg/day citalopram for 10 days and citalopram, and its des- and didesmethylmetabolites were assayed in serum and urine. Using a nonenantioselective analytical method (high-performance liquid chromatography), it was shown that the citalopram elimination partially depends on the mephenytoin oxygenase, since steady-state serum concentration, half-life, and area under the serum concentration/time curve for citalopram were significantly higher in poor metabolizers of mephenytoin than in extensive metabolizers of mephenytoin. Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively). It was further indicated that the demethylation of desmethylcitalopram to dide...Continue Reading

Citations

Jun 20, 2006·European Archives of Psychiatry and Clinical Neuroscience·Norbert Thuerauf, Jens Lunkenheimer
Nov 5, 2010·International Journal of Clinical Pharmacy·Bob WilffertUNKNOWN KNMP working group Pharmacogenetics
Mar 3, 2011·International Journal of Clinical Pharmacy·Bob WilffertUNKNOWN KNMP working group Pharmacogenetics
Feb 1, 1994·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·E Spina, A P Caputi
Aug 1, 1994·Journal of Pharmacological and Toxicological Methods·R T CouttsG B Baker
May 14, 1998·Neuroscience and Biobehavioral Reviews·G B BakerR T Coutts
Feb 16, 2000·Pharmacology & Therapeutics·C Hiemke, S Härtter
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Meera VaswaniSubramanyam Ramesh
Nov 26, 1999·European Psychiatry : the Journal of the Association of European Psychiatrists·S PallantiL M Koran
Sep 5, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·K Brøsen, C A Naranjo
May 15, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Lina SteinacherPierre Baumann
Sep 5, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pierre BaumannChin B Eap
Sep 2, 2010·Journal of Medicinal Chemistry·Fraser F FlemingBrian C Shook
Oct 27, 2001·British Journal of Clinical Pharmacology·J A Goldstein
Nov 17, 1994·The New England Journal of Medicine·L Gram
Jun 11, 2004·Clinical Neuropharmacology·Luigi M SpecchioLuigi Murri
Feb 16, 2007·Pharmacogenetics and Genomics·Kaori NakamotoXiao-Bo Zhong
Dec 31, 2010·Pharmacogenetics and Genomics·David A MrazekRichard M Weinshilboum
May 7, 2011·Pharmacogenetics and Genomics·Katrin SangkuhlRuss B Altman
Feb 1, 1996·British Journal of Clinical Pharmacology·S V OttonE M Sellers
Feb 1, 1996·Acta Psychiatrica Scandinavica·U A MeyerA Delini-Stula
Jan 1, 1997·Acta Psychiatrica Scandinavica. Supplementum·L BertilssonG Tybring
Apr 1, 1996·Pharmacology & Toxicology·M L Catterson, S H Preskorn
Mar 28, 2001·Journal of Clinical Pharmacology·F LarsenK F Overø
Dec 28, 1999·Pharmacotherapy·B A HamelinM L Crismon
Jul 25, 2000·Pharmacotherapy·A Nolting, W Abramowitz
Sep 12, 2002·Clinical Pharmacokinetics·Zeruesenay DestaDavid A Flockhart
Mar 6, 2003·CNS Drugs·Dalu Mancama, Robert W Kerwin
Sep 12, 2009·Clinical Pharmacokinetics·F F Tessa VerversAlfred F A M Schobben
Apr 23, 2008·The Journal of Clinical Psychiatry·Dorothy K SitKatherine L Wisner
Jun 3, 2014·BMC Medicine·Naji C SalloumJohn R Kelsoe
May 27, 2014·European Journal of Clinical Pharmacology·Ragnhild Birkeland WaadeEspen Molden
Feb 24, 2001·Clinical Therapeutics·S E MøllerP E Rolan
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Feb 3, 2007·Expert Opinion on Drug Metabolism & Toxicology·John L BlackDavid A Mrazek

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.